STADA

What STADA does

STADA Arzneimittel AG is a German pharmaceutical company headquartered in Bad Vilbel, operating since 1895 with a three-pillar strategy spanning Consumer Healthcare, Generics, and Specialty Pharmaceuticals. The Consumer Healthcare pillar markets OTC brands including Nizoral (anti-dandruff, Europe's No. 1 scalp health brand), Grippostad, Zoflora, Hirudoid, Silomat, and SNUP, alongside recently acquired local hero brands from Sanofi, GSK, Orifarm, and Walmark. The Generics pillar makes STADA the fourth-largest generics manufacturer in Europe by sales, supplying affordable off-patent medicines that account for seven of every ten prescriptions written in Europe. The Specialty Pharmaceuticals pillar delivers biosimilars (adalimumab, bevacizumab, pegfilgrastim, ranibizumab, golimumab, teriparatide, ustekinumab) co-developed with partners including Alvotech, Xbrane, mAbxience, Bio-Thera, and CuraTeQ, plus orphan and specialty treatments such as Kinpeygo for IgA nephropathy and device-driven combination therapies for Parkinson's disease. STADA also operates a Diagnostics line for personalized drug therapy.

STADA generates revenue through product sales across more than 100 countries via national sales companies, direct pharmacy and retail distribution, online pharmacies, and channel partner agreements — most notably a strategic distribution and marketing arrangement with Sanofi covering 20 European and 10 Eurasian countries. The portfolio spans over 25,000 SKUs, manufactured in Germany, Romania, Serbia, and soon Saudi Arabia, and sold to both B2B customers (pharmacies, healthcare systems, prescribers) and B2C consumers via OTC self-medication channels. Following a 2017 take-private by Bain Capital and Cinven, STADA was acquired by London-based private equity firm CapVest Partners in a transaction completed on March 31, 2026, valued at approximately $11.28 billion. As of December 31, 2025, STADA employed 11,749 people worldwide.

Name

STADA

Legal name

STADA Arzneimittel AG

Website

https://stada.com

Company type

Private

Founded year

1895

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

STADA is a German pharmaceutical company operating since 1895 across three pillars: Consumer Healthcare OTC brands (Nizoral, Grippostad), Generics (4th-largest in Europe), and Specialty Pharmaceuticals including biosimilars. Products reach pharmacies and consumers in over 100 countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceuticals
• Consumer healthcare products
• Biosimilar medicines
• Specialty pharmaceuticals
• Pharmaceutical manufacturing

Headquarters

HQ city

Bad Vilbel

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generics: Sales of affordable generic pharmaceuticals that contain the same active pharmaceutical ingredients as patented products but at substantially lower prices. STADA ranks as the fourth-largest manufacturer and supplier of generics in Europe by sales.
2. Consumer Healthcare: Sales of over-the-counter (OTC) products including Nizoral, Zoflora, Grippostad, Silomat, Hirudoid, and other brands for self-medication. Includes vitamins, minerals, supplements, derma products, cough/cold remedies, pain relief, and sleep aids.
3. Specialty Pharmaceuticals: Sales of specialty medicines including biosimilars for autoimmune diseases, cancer, osteoporosis, ophthalmic conditions, and innovative treatments for rare diseases like IgA nephropathy and Parkinson's disease.
4. Product Portfolio: STADA operates with over 25,000 SKUs in its product portfolio across Consumer Healthcare, Generics, and Specialty Pharmaceuticals, selling in over 100 countries worldwide.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

STADA manufactures and distributes a three-pillar pharmaceutical portfolio consisting of Consumer Healthcare (OTC brands such as Nizoral, Grippostad, Zoflora, Silomat, Hirudoid), Generics (affordable off-patent medicines where it ranks fourth-largest in Europe), and Specialty Pharmaceuticals (biosimilars including GOTENFIA, Adalimumab, Bevacizumab, Movymia, plus orphan drug Kinpeygo and Parkinson's combination therapy). Products are sold across more than 100 countries via national sales companies, pharmacy distribution networks, and strategic distribution partnerships.

Product overview

STADA is a German pharmaceutical company with a three-pillar strategy consisting of Consumer Healthcare products, Generics, and Specialty Pharmaceuticals. The Consumer Healthcare portfolio includes well-known brands such as Nizoral® (anti-dandruff), Grippostad® (cold/flu), Zoflora® (disinfectants), SNUP® (nasal spray), Silomat® (cough relief), and Lunestil® (sleep support). The Specialty Pharmaceuticals segment delivers innovative medicines for chronic, complex, or rare conditions including biosimilars (GOTENFIA®, Adalimumab biosimilar, Bevacizumab biosimilar), treatments for Parkinson's disease, and orphan drugs like Kinpeygo for rare kidney disease. The Generics segment is STADA's backbone since 1895, ranking as the fourth-largest generics supplier in Europe. STADA operates in over 100 countries with a portfolio spanning more than 25,000 SKUs, supported by manufacturing, sourcing, and distribution networks.

Differentiator

Problem solved

Functional benefit

Brands

• Nizoral: Medical treatment against dandruff. Top-selling consumer healthcare brand.
• Zoflora
• Grippostad
• SNUP
• Silomat
• Hirudoid
• Lunestil
• Oilatum
• Synthol
• Cetebe
• Orofar
• BIOPRON
• Nycoplus
• Apovit
• Magnecaps
• Vitrum
• Cetraben
• Movymia
• Kinpeygo

Products and services

• Generics Portfolio Affordable off-patent generic pharmaceuticals containing the same active ingredients as patented originator products, supplied at substantially lower prices. STADA ranks as the fourth-largest manufacturer and supplier of generics in Europe by sales, with seven out of ten medicines prescribed in Europe being generics accounting for roughly 30% of pharmaceutical expenditure.
• GOTENFIA (Golimumab Biosimilar) Biosimilar to Johnson & Johnson's SIMPONI, approved in Europe for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Developed and marketed by STADA with development partner Bio-Thera.
• Kinpeygo Orphan drug and the first EU-approved treatment for primary immunoglobulin A nephropathy (IgA nephropathy) in adults, a rare kidney disease. Launched by STADA in 2022 in partnership with Calliditas Therapeutics.
• Movymia (Teriparatide Biosimilar) Teriparatide biosimilar for the treatment of osteoporosis, developed in collaboration with Richter-Helm-BioTec and launched across 24 countries.
• Bevacizumab Biosimilar Oncology biosimilar for cancer treatment, launched in partnership with mAbxience and available to oncologists and patients across Europe including Germany and Netherlands.
• Parkinson's Disease Combination Therapy (Levodopa/Carbidopa/Entacapone) Device-driven triple combination therapy for late-stage Parkinson's disease using modern pump technology, providing an innovative treatment option for advanced Parkinson's patients.
• Adalimumab Biosimilar High-concentration adalimumab biosimilar for autoimmune diseases, brought to European patients through STADA's strategic partnership with Iceland's Alvotech.
• Ranibizumab Biosimilar Ophthalmology biosimilar developed with Xbrane for ophthalmologic conditions, brought to European patients through the Xbrane partnership.
• Silapo (Epoetin Zeta Biosimilar) Epoetin zeta biosimilar for symptomatic anemia associated with chronic kidney failure and chemotherapy-induced anemia, originally introduced as STADA's first biosimilar.
• Nizoral Anti-dandruff medicated shampoo and scalp care brand, marketed by STADA across the EMEA region with category-leading positions. Celebrated 40 years in 2026 and named Product of the Year 2026 in Italy.
• Grippostad Over-the-counter medicine against flu infections and colds, positioned among the top sellers in its product category in STADA's markets.
• Zoflora Disinfectant brand for keeping households clean from harmful bacteria, sold through consumer healthcare channels.
• SNUP Nasal decongestant spray for relieving nasal congestion during colds, distributed as part of STADA's cough and cold portfolio.
• Silomat Cough relief product providing relief from irritating, dry coughs, sold as a leading brand in the consumer cough and cold category.
• Hirudoid Topical treatment for venous insufficiency and phlebology conditions, part of STADA's pain and relief portfolio.
• Lunestil Sleep-support product for the short-term treatment of acute sleep disorders, sold as part of the calm and sleep consumer healthcare category.
• Synthol Topical pain relief product in STADA's pain and relief consumer healthcare portfolio.
• Cetebe Vitamins, minerals, and gastro product supporting digestive health and nutritional supplementation as part of STADA's consumer healthcare portfolio.
• Oilatum Derma brand product line for skincare, including treatments formulated for dry and eczema-prone skin.
• BIOPRON Premium probiotic product line for gut health and digestive wellness, marketed within STADA's vitamins, minerals, and gastro category.
• Nycoplus (VMS Brand Norway) Market-leading pharmacy vitamins, minerals, and supplements line in Norway, acquired from Orifarm as part of STADA's first deal under CapVest ownership.
• Apovit (VMS Brand Denmark) Market-leading vitamins, minerals, and supplements range in Danish pharmacies, acquired from Orifarm in June 2026.
• Magnecaps (VMS Brand Belgium) Popular magnesium-based supplements brand in Belgium, acquired from Orifarm in June 2026.
• Vitrum (VMS Brand Poland) Broad vitamins, minerals, and supplements brand in Poland, acquired from Orifarm in June 2026.

Quantifiable outcome

• EUR 4.3 billion adjusted group revenues in FY 2025
• +6 more outcomes

Named customers5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• EnzymaticaminorChannel Partner/ Reseller/ Distributor · 1 April 2026Partnership agreement for Germany and Austria for distribution of Enzymatica products, signed April 1, 2026.
• CuraTeQminorStrategic or Co-development Partner · 16 November 2025STADA struck deal with CuraTeQ for neutropenia biosimilars in Europe, announced March 30, 2026.
• XbranecoreStrategic or Co-development Partner · 1 April 2023Partnership with Sweden's Xbrane to bring the biologic ophthalmic medicine ranibizumab to patients in Europe, supporting patient access to ophthalmologic treatments.
• AdalvominorStrategic or Co-development Partner · 1 January 2023Extension of strategic partnership with Adalvo to obtain commercial rights in Europe to five additional active ingredients in therapeutic categories including oncology and diabetes.
• SanoficoreChannel Partner/ Reseller/ Distributor · 1 July 2021STADA and Sanofi entered into consumer healthcare distribution agreements to distribute and market Sanofi's entire Consumer Healthcare portfolio in 20 European countries as well as 10 countries in the Eurasia region. This followed a transaction where STADA acquired 16 well-established consumer healthcare brands from Sanofi in Europe.
• Calliditas TherapeuticscoreStrategic or Co-development Partner · 1 January 2021STADA and Calliditas partnered to obtain the first approval in the European Union for a treatment for the rare kidney disease immunoglobulin A nephropathy (IgAN), resulting in Kinpeygo launch.
• mAbxiencecoreStrategic or Co-development Partner · 1 January 2021Partnership with mAbxience to expand specialty oncology portfolio with biosimilar bevacizumab launch. Cancer treatment available to oncologists and patients in Germany and Netherlands, with launches in other European countries following.
• AlvotechcoreStrategic or Co-development Partner · 1 September 2020Strategic partnership with Iceland's Alvotech to expand patient access to adalimumab (biosimilar for autoimmune conditions) in Europe. Also partnered to submit marketing authorization application for ustekinumab (AVT04) for immunology agent.
• Richter-HelmminorStrategic or Co-development Partner · 1 August 2019Collaboration with Richter-Helm-BioTec GmbH & Co.KG on in-licensing teriparatide for treatment of osteoporosis, expanding biosimilar portfolio with Movymia launched in 24 countries.
• GlaxoSmithKline (GSK)coreChannel Partner/ Reseller/ Distributor · 1 January 2019STADA acquired 15 well-established consumer healthcare brands from GSK across more than 40 countries, following a previous deal for five non-prescription skincare brands. This strengthened STADA's skin care business in Europe.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Sandoz: Sandoz, spun out of Novartis in 2023, is the global leader in generics and one of the largest biosimilars players. Direct competitor to STADA in European generics, biosimilars (adalimumab, etanercept, infliximab), and selected consumer health categories with comparable three-pillar structure.
• Dr. Reddy's Laboratories: India-based Dr. Reddy's is a leading global generics and biosimilars player with active European operations. Comparable in generic small molecules, biosimilars (rituximab, bevacizumab), and increasingly in differentiated formulations sold through European tenders similar to STADA.
• Perrigo Company: Perrigo is a leading global consumer healthcare (OTC) generics and self-care products company. Overlaps directly with STADA's Consumer Healthcare pillar (derma, cough/cold, personal care), competing in pan-European retailer and pharmacy channels.
• Teva Pharmaceutical Industries: Teva is the world's largest generics manufacturer with significant European presence and a biosimilars pipeline. Directly comparable to STADA across off-patent small molecules, biosimilars, and increasingly in specialty, and competes head-to-head in European tenders.
• KRKA: Slovenian KRKA is a top-5 European generics manufacturer with a strong consumer health (OTC) portfolio. Comparable vertical integration from API to finished dose, multi-country European distribution, and OTC brand-building approach mirroring STADA's three-pillar model.
• Viatris: Viatris (formed via Mylan-Upjohn merger) is a top-3 global generics and biosimilars player with a strong European footprint. Direct competitor across generics, biosimilars, and branded complex formulations serving the same pharmacy and institutional channels as STADA.
• Zentiva: Prague-based Zentiva is one of Europe's largest pure-play generics manufacturers with strong positions in Central and Eastern Europe. Direct peer in EU generics tenders and overlapping biosimilars strategy with privately-held ownership structure similar to STADA's.

Broad incumbents

• Bayer Consumer Health: Bayer's Consumer Health division includes leading OTC brands (Aspirin, Claritin, Aleve) and competes directly with STADA in European OTC categories. Larger and broader portfolio than STADA but overlapping in cough/cold, dermatology, and analgesics self-medication segments.
• Sanofi (Consumer Healthcare): Sanofi's Consumer Healthcare business is both an indirect competitor and STADA's largest distribution partner across 30 European/Eurasian countries. Comparable in OTC, vitamins, and derma categories with broader pharma backing and broader portfolio reach than STADA.

Emerging players

• Alvotech: Iceland-based Alvotech is a pure-play biosimilars developer and direct co-development partner of STADA (adalimumab, ustekinumab). Comparable in biosimilar pipeline focus and increasingly competes with STADA for European commercialization rights as both partner and competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/stada
• YouTubeyoutube.com/user/STADAArzneimittelAG
• Facebookfacebook.com/Stada
• LinkedInlinkedin.com/company/stada
• Instagraminstagram.com/stadagroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STADA